41![Shionogi Launches Injectable Analgesics for Cancer Pain, “OxiFast® Injection 10mg” and “OxiFast® Injection 50mg” Osaka, Japan, May 28, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Tesh Shionogi Launches Injectable Analgesics for Cancer Pain, “OxiFast® Injection 10mg” and “OxiFast® Injection 50mg” Osaka, Japan, May 28, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Tesh](https://www.pdfsearch.io/img/2ba031307f7e7dd6ce9359f68d4a385c.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:22
|
---|
42![Shionogi Launches “Endoxan® Powder 100mg for Oral” for Nephrotic Syndrome Osaka, Japan, July 30, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) tod Shionogi Launches “Endoxan® Powder 100mg for Oral” for Nephrotic Syndrome Osaka, Japan, July 30, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) tod](https://www.pdfsearch.io/img/1ef5ba0f419f8704f1ed5ed41fdff3cf.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:23
|
---|
43![](https://www.pdfsearch.io/img/7b5812bc8696bafaa11c3923247efc9b.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:24
|
---|
44![EZOSE
SCIENCES
FORMS
ALLIANCE
WITH
FAST
FORWARD
TO
DISCOVER
BIOMARKERS
TO
DIAGNOSE
MULTIPLE
SCLEROSIS
EZOSE
SCIENCES
FORMS
ALLIANCE
WITH
FAST
FORWARD
TO
DISCOVER
BIOMARKERS
TO
DIAGNOSE
MULTIPLE
SCLEROSIS](https://www.pdfsearch.io/img/a4f849e3fa932855933a55325a75c864.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:24
|
---|
45![ILDONG PHARMACEUTICAL Receives a Marketing and Manufacturing Approval for Pirespa® 200mg Tablet Idiopathic Pulmonary Fibrosis Treatment Osaka, Japan, August 8, Shionogi & Co., Ltd. (Head Office: Osaka; President: ILDONG PHARMACEUTICAL Receives a Marketing and Manufacturing Approval for Pirespa® 200mg Tablet Idiopathic Pulmonary Fibrosis Treatment Osaka, Japan, August 8, Shionogi & Co., Ltd. (Head Office: Osaka; President:](https://www.pdfsearch.io/img/78f43e369cafc09caa58b1cae1c0d181.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:25
|
---|
46![January 25, 2010 Shionogi & Co., Ltd. Shionogi Supports Relief Efforts for Haiti Earthquake Victims Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President: Isao Teshirogi; hereafter “Shionogi”) today announced th January 25, 2010 Shionogi & Co., Ltd. Shionogi Supports Relief Efforts for Haiti Earthquake Victims Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President: Isao Teshirogi; hereafter “Shionogi”) today announced th](https://www.pdfsearch.io/img/4e803c639babe8ca4e54d02fce846402.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:18
|
---|
47![Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside](https://www.pdfsearch.io/img/ea7e0a57ead0c5e1fe795ddfcd1c9524.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:24
|
---|
48![Shionogi starts a screening program for new anti-TB compounds Osaka, Japan, June 3, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that Shionogi starts a screening program for new anti-TB compounds Osaka, Japan, June 3, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that](https://www.pdfsearch.io/img/9e478a46b9c06f12cee0f6b7001e5e31.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:23
|
---|
49![ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P](https://www.pdfsearch.io/img/c5e756c483bd9b39f54c6028d7480e61.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2015-01-27 14:49:56
|
---|
50![Shionogi Receives Approvals of Pediatric Use and Additional Indication for Purulent Meningitis of Carbapenem-Type Antibiotic, ® “Finibax 0.25g/0.5g for Intravenous Drip Infusion” and “Finibax® 0.25g Kit for Intra Shionogi Receives Approvals of Pediatric Use and Additional Indication for Purulent Meningitis of Carbapenem-Type Antibiotic, ® “Finibax 0.25g/0.5g for Intravenous Drip Infusion” and “Finibax® 0.25g Kit for Intra](https://www.pdfsearch.io/img/55f3ef96b885ed33289cb8c8895f4ffa.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:21
|
---|